# Ladarixin as Adjunctive Therapy to Improve Insulin Sensitivity and Glucometabolic Outcomes in Type 1 Diabetes

> **NCT05035368** · PHASE2 · WITHDRAWN · sponsor: **Dompé Farmaceutici S.p.A**

## Conditions studied

- Type I Diabetes

## Interventions

- **DRUG:** Ladarixin
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05035368
- **Lead sponsor:** Dompé Farmaceutici S.p.A
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-09-30
- **Primary completion:** 2023-06
- **Final completion:** 2023-06
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Dompé decided to withdraw LDX0121 following an internal re-planning and an extensive review of the study design.

At the time of withdrawal, no site had been activated and the drug had not been sent to investigators. No patients had been enrolled.
- **Last updated:** 2023-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05035368

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05035368, "Ladarixin as Adjunctive Therapy to Improve Insulin Sensitivity and Glucometabolic Outcomes in Type 1 Diabetes". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT05035368. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*